AirJoule Technologies: A Cool Shot at a Multibagger AirJoule Technology is on track to comercialize its technology and unleadh a torrent of demand, hyper revenue growth, and a quick path to profits. MarketBeat · Jun 9
Walmart's No. 2 Ranking Hides a Digital Transformation Story Walmart is evolving beyond retail through advertising, e-commerce, and Sam's Club digital innovation. Learn why WMT may deserve a higher valuation MarketBeat · Jun 9
Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Campbell's Soup Company is at rock bottom and too cheap to ignore, yielding more than 7% with a business recovery taking hold. MarketBeat · Jun 9
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development. MarketBeat · Jun 9
Oxford Instruments H2 Earnings Call Highlights Oxford Instruments (LON:OXIG) said it delivered a stronger second half after a difficult start to the year, as improving demand from commercial semiconductor customers helped offset weaker academic markets and geopolitical uncertainty. Chief Executive Richard Tyson told investors the company was “r MarketBeat · Jun 9
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru MarketBeat · Jun 9
Zepp Health Q1 Earnings Call Highlights Zepp Health (NYSE:ZEPP) reported a stronger start to 2026, with management pointing to new Amazfit product launches, a higher-end product mix and expanding positioning in hybrid training as the main drivers of first-quarter growth. On the company’s earnings call, Founder and Chief Executive Officer MarketBeat · Jun 9
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build “a multiple product MarketBeat · Jun 9
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas MarketBeat · Jun 9
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT. Mark Singleton, Bioventus’ senior vice president and chief financi MarketBeat · Jun 8
Vail Resorts Q3 Earnings Call Highlights Vail Resorts (NYSE:MTN) said historically poor weather across the Western United States continued to weigh on fiscal third-quarter results, pressuring visitation and revenue at its mountain resorts while management emphasized that its advance commitment pass model and cost controls helped cushion th MarketBeat · Jun 8
Mama's Creations Q1 Earnings Call Highlights Mama's Creations (NASDAQ:MAMA) reported sharply higher first-quarter fiscal 2027 results, with management pointing to new retail placements, the Crown I acquisition and broader customer growth as the main drivers, even as gross margins were pressured by launch-related costs. Chairman and CEO Adam L MarketBeat · Jun 8
Gloo Q1 Earnings Call Highlights Gloo (NASDAQ:GLOO) reported fiscal first-quarter revenue and adjusted EBITDA ahead of its own guidance and Wall Street consensus, as executives pointed to momentum from large strategic customers, recent acquisitions and growing demand for AI-enabled technology and marketing tools across faith-based MarketBeat · Jun 8
Mission Produce Q2 Earnings Call Highlights Mission Produce (NASDAQ:AVO) said its fiscal second quarter was pressured by an unusually high-supply avocado market, particularly from Mexico, which drove prices to multi-year lows and compressed margins despite higher avocado volumes. President and Chief Executive Officer John Pawlowski, who form MarketBeat · Jun 8
MarketBeat · Jun 8 Motorcar Parts of America Q4 Earnings Call Highlights Motorcar Parts of America (NASDAQ:MPAA) reported stronger fiscal fourth-quarter and full-year results, with management pointing to sales momentum, new business commitments and improving profitability as key drivers heading into fiscal 2027. Chairman, President and Chief Executive Officer Selwyn Jof
MarketBeat · Jun 8 3 Stocks With Fresh Catalysts to Watch Before the July 4 Broadcom, Palo Alto Networks, and Planet Labs each reported strong results and offer potential upside as investors position for the second half of 2025.
MarketBeat · Jun 8 Amprius Insiders Are Selling: Should Investors Be Worried? Amprius Technology is on track to set a new all-time high later this year after it reports Q2 results and guidance. Short interest suggests a squeeze is possible.
MarketBeat · Jun 8 A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus A weaker dollar means international revenue can have a bigger impact, and these companies might be positioned to take advantage of an otherwise tough situation.
MarketBeat · Jun 8 Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate
MarketBeat · Jun 8 Graham Q4 Earnings Call Highlights Graham (NYSE:GHM) reported record fiscal 2026 revenue, orders and backlog, with management pointing to strong demand in defense, improving momentum in space and contributions from recent acquisitions as the company enters fiscal 2027. On the company’s fiscal fourth-quarter earnings call, President
MarketBeat · Jun 8 A Market Rotation Toward Quality Will Benefit These 3 ETFs "Quality" stocks may be better able to withstand market turbulence thanks to stable earnings, strong balance sheets, and more; these ETFs aim to find them.
MarketBeat · Jun 8 3 Multi-Metal Stocks for Income and Long-Term Growth These three metals stocks offer exposure to copper, gold, and silver while combining growth potential with income opportunities
MarketBeat · Jun 8 Optical Cable Q2 Earnings Call Highlights Optical Cable (NASDAQ:OCC) reported sharply higher fiscal second-quarter sales and profit, with management citing strength in enterprise, data center and severe-duty markets, as well as improved manufacturing leverage. On the company’s fiscal 2026 second-quarter earnings call, President and Chief E
MarketBeat · Jun 8 Nebius Is Up Nearly 175% This Year—Here's What's Driving the Latest Run Nebius Group is up 175% year-to-date, driven by an NVIDIA endorsement, a 5.6% hedge fund stake, and 684% year-over-year Q1 revenue growth.
MarketBeat · Jun 8 Technology Stocks Just Got Cheaper—Here Are 5 Mega-Caps Worth a Closer Look A major market-wide selloff on Friday compressed valuations across several mega-cap technology stocks, creating potential long-term opportunity.